(Q37964935)

26 August 2017

title

Role of randomized phase III trials in an era of effective targeted therapies (English)

1 reference

26 August 2017

main subject

phase III clinical trial

0 references

author name string

Manish R Sharma

series ordinal

1

1 reference

26 August 2017

Richard L Schilsky

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

6 December 2011

1 reference

Nature Reviews Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

208-214

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Accelerated approval of oncology products: the food and drug administration experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Randomized phase II trials: a long-term investment with promising returns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Availability of experimental therapy outside oncology randomized clinical trials in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Changing end points in breast-cancer drug approval--the Avastin story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Unmeasured costs of a child's death: perceived financial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Seamlessly expanding a randomized phase II trial to phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Outcome--adaptive randomization: is it useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Equipoise and the Dilemma of Randomized Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Balancing Access and Evaluation in the Approval of New Cancer Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Accrual to cancer clinical trials in the era of molecular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Minimizing bias in randomized trials: the importance of blinding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Adaptive clinical trials in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule

31 March 2020

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

Equipoise: asking the right questions for clinical trial design

1 reference

12 December 2020

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

1 reference

12 December 2020

10.1038/NRCLINONC.2011.190

Identifiers

DOI

1 reference

26 August 2017

1 reference